Company intelligence / Profile preview

Ymmunobio

Ownership: Private
Development stage: Preclinical

Overview

YB-200 has received orphan drug status by the US FDA for the treatment of liver cancer in February 2023. The company has demonstrated anti-tumor activity of its lead asset YB-200 in validated models showing correlation with changes in the immune compartment of the tumor microenvironment[5][6].

Therapeutic areas: Oncology
Modalities: AntibodiesADCs (Antibody-Drug Conjugates)RadiopharmaceuticalsBiTEs (Bispecific T-cell Engagers)Diagnostics
Industry: Biotech

Drug pipeline

9 assets

YB-800

Preclinical

8 more assets in the full pipeline.

Request access →

Partnerships

EVIIVE (for Liquid Biopsy development)[2]

Beyond the preview

Go deeper on Ymmunobio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ymmunobio.

Explore the full profile